Dr. Ferozuddin Feroz,
The Minister of Public Health
Ministry of Public Health
Great Masoud Road
Kabul
Afghanistan

7 December 2016

Decision Letter: Product switch grant for change in presentation of Pneumococcal vaccine

Your Excellency,

I am writing in relation to Afghanistan’s request for a product switch grant to support the change in presentation of Pneumococcal vaccine, from PCV13 1 dose per vial to PCV13 4 doses per vial. I am pleased to inform you that Gavi has approved Afghanistan’s request for a product switch grant, subject to conditions and requirements as specified in Appendix A to this letter.

Please do not hesitate to contact my colleague Ms Anne Cronin, Senior Country Manager for Afghanistan, at acronin@gavi.org if you have any questions or concerns.

Yours sincerely,

Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
    The EPI Manager
    WHO Country Representative
    UNICEF Country Representative
    Regional Working Group
    WHO HQ
    UNICEF Programme Division
    UNICEF Supply Division
**Appendix A**

**Afghanistan Support for Pneumococcal Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Afghanistan

2. **Grant number:** 17-AFG-12c-X / 1819-AFG-12d-X/ 17-AFG-25a-Y

3. **Date of Decision Letter:** 07/12/2016

4. **Date of the Partnership Framework Agreement:** 30/04/2013

5. **Programme title:** New Vaccine Support (NVS), Pneumococcal Routine

6. **Vaccine type:** Pneumococcal

7. **Requested product presentation and formulation of vaccine:** Pneumococcal (PCV13), 1 dose per vial, LIQUID and PCV13, 4 doses per vial, LIQUID¹

8. **Programme duration²:** 2013 - 2019

9. **Programme Budget (indicative):** (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2013-2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>Total³</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>69,835,261</td>
<td>17,443,500</td>
<td>16,169,000</td>
<td>17,272,000</td>
<td>120,719,761</td>
</tr>
</tbody>
</table>

10. **Vaccine introduction grant (in US$):** Country qualifies for a product switch grant of up to US$ 406,500 to support the PCV switch. The funding will be transferred upon submission and approval of the budget for utilisation of the product switch grant.

11. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement, if applicable)⁵

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2013-2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Pneumococcal vaccines doses</td>
<td></td>
<td>4,646,500</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>69,835,261</td>
<td>17,443,500</td>
</tr>
</tbody>
</table>

¹ Country requested a switch to PCV13, 4 dose vial, in April 2017. The timing of the first shipments of PCV13, 4 dose vial, will be determined during the development of the 2017 shipment plan based on your desired timing, the stock of the existing presentation of PCV, supply availability, and programmatic readiness to switch. Wastage has been estimated at 10% to align with WHO indicative wastage for the PCV13 4 dose vial and co-financing is aligned with your desired presentation in anticipation of the switch.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁵ This is the amount that Gavi has approved.
12. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. **Self-procurement:** Not applicable

14. **Co-financing obligations:** Reference code: 17-AFG-12c-X-C / 1819-AFG-12d-X-C
According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>285,400</td>
<td>319,000</td>
<td>327,400</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>941,587</td>
<td>988,300</td>
<td>1,014,754</td>
</tr>
<tr>
<td><strong>Total co-financing payments (US$)</strong> (including freight)</td>
<td>986,500</td>
<td>1,004,500</td>
<td>1,031,500</td>
</tr>
</tbody>
</table>

15. **Operational support for campaigns:** Not applicable

16. **Additional reporting requirements:**

   **Reports and other information** | **Due dates**
--- | ---
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | 15 May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Secretariat

17. **Financial clarifications:** Not applicable

18. **Other conditions:** Not applicable

Signed by, 

Hind Khatib-Othman
Managing Director, Country Programmes
7 December 2016